Does Enasidenib Mesylate Interact with Anti Fungal Agents That Are Cyp3a4 Substrates?
CDI records a major classification for Enasidenib Mesylate and Anti Fungal Agents That Are Cyp3a4 Substrates. The stored summary is: Do not administer enasidenib with anti-fungal agents that are CYP3A substrates due to expected loss of antifungal efficacy. The mechanism involves cyp3a induction leading to decreased antifungal exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.
- Stored CDI classification
- Major
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A induction leading to decreased antifungal exposure
What To Tell Your Doctor or Pharmacist
If you are taking Enasidenib Mesylate and your doctor is considering prescribing Anti Fungal Agents That Are Cyp3a4 Substrates (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider